STOCK TITAN
  1. Home
  2. News
  3. NVS

Novartis AG - $NVS STOCK NEWS

Welcome to our dedicated page for Novartis news (Ticker: $NVS), a resource for investors and traders seeking the latest updates and insights on Novartis stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novartis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novartis's position in the market.

News
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Rhea-AI Summary
Novartis presents positive interim results for Fabhalta in treating IgA nephropathy, showing a 38.3% proteinuria reduction compared to placebo, with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
-
News
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Rhea-AI Summary
Novartis announces positive results from V-INITIATE trial showing Leqvio's significant reduction in LDL-C levels for ASCVD patients unable to reach their goal on statin therapy alone. The safety profile of Leqvio was consistent with previous studies, reinforcing the need for more aggressive LDL-C lowering in ASCVD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
News
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
Rhea-AI Summary
Novartis (NVS) reports favorable results from the extension period of the pivotal Phase III APPLY-PNH trial of oral monotherapy Fabhalta in adults with paroxysmal nocturnal hemoglobinuria (PNH). Continuous Fabhalta treatment enabled sustained hemoglobin-level increases to near-normal, blood transfusion avoidance, and reduced patient-reported fatigue. Fabhalta was recently approved by the FDA for adults with PNH, including for both previously treated and treatment-naive patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
clinical trial
News
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Rhea-AI Summary
Novartis (NVS) receives FDA approval for Fabhalta, an oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is a Factor B inhibitor that demonstrates superior hemoglobin improvement and transfusion avoidance rates over anti-C5 treatments. The approval is based on the Phase III APPLY-PNH and APPOINT-PNH trials, showing significant efficacy and safety in treating PNH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
fda approval
-
News
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
Rhea-AI Summary
Defence Therapeutics Inc. (OTCPK: DTCFF): Oncology drugs market growth is driven by rising cancer prevalence, new drug launches, and research activities. The global oncology drugs market size is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0%. Defence Therapeutics submitted an Investigational New Drug (IND) application for AccuTOX®, an injectable anticancer molecule, with potential to combat solid tumors. The company aims to advance AccuTOX® into clinical trials, with the primary objective of identifying therapeutic dosing range for co-administration with Opdulag®, a BMS product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
News
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
Rhea-AI Summary
Novartis is conducting a voluntary nationwide recall of one lot of Sandimmune® Oral Solution due to crystal formation that could result in incorrect dosing. No adverse events reported. Contact healthcare provider if affected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
News
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News
AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
management
-
News
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
Stock NVS logo
Novartis AG

NYSE:NVS

NVS Rankings

#44 Ranked by Market Cap
#1123 Ranked by Stock Gains
#894 Ranked by Dividends

NVS Stock Data

202.14B
1.96B
0%
6.93%
0.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Basel

About NVS

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.